Virometix closes Extension Financing Round and appoints Harry Welten as new independent Board Member
Schlieren, Switzerland (August 28, 2017)
– Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of Harry Welten, MBA as new independent member of its Board of Directors.
> View complete release
> Download PDF release
Mr. Welten brings in more than 20 years of international senior executive experience, 17 of which as Chief Financial Officer in biotech. He is CFO of Kuros AG (formerly Cytos) and a member of the Board of Kanyos, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. Mr. Welten will replace Prof. John Robinson, who stepped down from the Board of Directors earlier this year to now support the company as a member of the Scientific Advisory Board. With the appoint of Mr Welten, Virometix takes a further step in to enhance its professional expertise in the Board of Directors.
Mr Welten, stated „Joining Virometix’ Board of Directors is a true honor for me. I am looking very much forward to helping create value for people, shareholders and employees“
“We are delighted to have attracted additional funding from experienced investors and cordially welcome Harry Welten to our Board of Directors, said Arin Ghasparian, CEO of Virometix “With his background in finance he will be an excellent fit for us as we progress with our development.”
Pierre Morgon, Chairman of Virometix, added “With the successful completion of our financing rounds, Virometix is on course to deliver its objectives and to advance several vaccine and cancer immunotherapy candidates. Harry will bring pivotal experience and skills in terms of financial management and deal making at an important time of the life of the company”.
Virometix Closes Financing Round
Schlieren, Switzerland (May 19, 2017)
– Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector.
> View complete release
> Download PDF release
Virometix plans to use the new funds to expand its operations and progress its vaccine candidates for infectious and viral diseases and cancer to next inflections points, including the start of a phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent safety and strong efficiency in preclinical models. The financing round was substantially oversubscribed.
Dr Pierre A. Morgon, Chairman of the Board, said: “With this infusion of smart capital from investors experienced in healthcare, and the network of world-class experts supporting the company, Virometix is ideally positioned to leverage its attractive platform with its strong intellectual property position”.
“We are delighted to have received substantial support from our shareholders as well as several new private investors, said Arin Ghasparian, CEO of Virometix, „The new financing will enable us to advance our lead RSV vaccine candidate more rapidly into clinical development, to further define our solution in oncology immunotherapy, and further underpins the attractiveness of our value proposition. “
Emmanuel Savioz, recently appointed CFO, commented “This financing provides the resources we need to reach important value-inflection milestones in 2018 and beyond.”
Virometix announces new appointments
Schlieren, Switzerland (January 25, 2017)
– Virometix today announced the appointment of Dr. Pierre A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments Virometix is taking further steps to enhance professional expertise within the Board of Directors and senior management of the company. Furthermore, the Scientific Advisory Board has been strengthened with the addition of emeritus Prof. Paul-Henri Lambert, MD.
> View complete release
> Download PDF release
Dr. Pierre Morgon
is a doctor of pharmacy and MBA holder with additional qualifications in Business Law. He has over 30 years experience up to C-level positions in large life science companies, including Sanofi Pasteur, and biotech firms such as AJ-Biologics. In these roles, he has provided leadership in the construction and expansion of vaccine portfolios and partnerships, with turnaround initiatives and with financing for start-up vaccine companies. Dr. Morgon is also Regional Partner for Switzerland at Mérieux Développement, Non-Executive Director to the Board of Theradiag, as well as Non-Executive Director to the Board of Eurocine Vaccines.
Dr. Morgon stated: «I am thrilled to join Virometix at a pivotal phase where we will strive to demonstrate the value of the company’s broad proprietary technology, both in the field of vaccines and in cancer immunotherapy.»
Dr. Isaac Kobrin, MD
is an internist with 15 years experience in academic medicine both in Israel and the USA. With 23 years of experience in the Pharma industry, he was responsible for the worldwide clinical development of key compounds at Roche for 10 years and subsequently in Actelion for 13 years. In Actelion, Dr. Kobrin was the head of clinical development and member of the executive committee for 10 years and later he was appointed as Chief Medical Officer and Chairman of the Strategic and Portfolio Board of the company. During the last 4 years, Dr. Kobrin has been supporting several Pharma and biotechnology companies as a Board member and/or as an advisor.
Emmanuel Savioz, MBA
has 15 years experience in financing and business. He co-founded and is a Board member of several high tech companies in Switzerland including Phi Pharma, HYT, and Preciflex. Over the past 7 years, Mr. Savioz arranged more than CHF 70 million of equity financing for high tech companies in Switzerland. Previously, he worked in New York as an investment banker in M&A handling large international transactions in consumer goods and healthcare. Emmanuel Savioz is former member of the Admission Committee of the MBA Program at IMD in Lausanne, Switzerland, and holds an MBA from the Haas School of Business, University of California at Berkeley, USA.
Prof. Paul-Henri Lambert, MD
is now associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI), past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO). In 1987, he was appointed as chief of Microbiology and Immunology at the World Health Organization and in 1994, chief of the Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. During this time he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.
«We are delighted to have some highly respected people like Dr. Morgon, Dr. Kobrin, Mr. Savioz and Prof. Lambert with their background and expertise come on board”, said Dr. Arin Ghasparian, CEO of Virometix. “They will be a perfect fit for us, as we are progressing very well with the development of our vaccine products, our scientific research and in discussions on future partnerships.»
Virometix further strengthens the Advisory Board
Zurich, Switzerland (April 12, 2016)
– Virometix today announced the addition of Dr. Martin L. Moore, an Assistant Professor at Emory University, Director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV) to its Advisory Board. Dr. Moore is a recognized leader in RSV research and has been running an NIH-funded laboratory in the Department of Pediatrics at Emory since 2008. His work on RSV vaccines was recognized as Emory University’s Innovation of the year in 2013.
Furthermore, the Advisory Board will be strengthened by the nomination of Dr. Urs Regenass, who has over 30 years’ experience in drug discovery. Most recently he worked as Senior Director Oncology at Actelion Pharmaceuticals. Before that Dr. Regenass was member of Novartis’ global research management board and VP Drug Discovery and CEO of the Switzerland site at Discovery Partners International, a CRO headquartered in San Diego. He obtained his PhD in Cell Biology at the Biocenter, University of Basel.